Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naive patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI)

Objectives:The aim of the article is to investigate the associations of disease duration and anti-cyclic citrullinated peptide antibody (ACPA) status with the effectiveness of abatacept in biologic-naive patients with rheumatoid arthritis (RA). Methods: We performed post hoc analyses of the Orencia (R) Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naive RA patients aged >= 20years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/>= 1year), or both. Results: SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration >= 1-year group, respectively. In the disease duration <1-year group, SDAI and J-HAQ tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models. Conclusions: These results suggest that starting abatacept within 1year of diagnosis was associated with greater effectiveness of abatacept in biologic-naive patients with RA and moderate disease activity.